Preferred Newer Oral Anticoagulants
Direct oral anticoagulants (DOACs)—specifically apixaban, dabigatran, edoxaban, and rivaroxaban—are preferred over warfarin for stroke prevention in atrial fibrillation, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. 1, 2
The Four DOACs to Choose From
The 2024 ESC Guidelines explicitly name the four available DOACs as preferred agents 1:
- Apixaban (Factor Xa inhibitor)
- Dabigatran (Direct thrombin inhibitor)
- Edoxaban (Factor Xa inhibitor)
- Rivaroxaban (Factor Xa inhibitor)
All four agents have demonstrated at least non-inferiority to warfarin for stroke prevention, with several showing superiority, and importantly, they carry lower risks of serious bleeding—particularly intracranial hemorrhage 2.
When DOACs Are NOT Appropriate
You must use warfarin instead of DOACs in two specific situations 1, 2:
- Mechanical heart valves - DOACs have shown inferior outcomes and increased thromboembolic events in this population 3
- Moderate-to-severe mitral stenosis - Insufficient evidence supports DOAC use in rheumatic valve disease
Patients with bioprosthetic valves can receive DOACs 2.
Dosing Strategy
Use full standard doses for DOACs unless the patient meets specific dose-reduction criteria 1. Common dose-reduction criteria typically include:
- Advanced age (≥80 years for some agents)
- Low body weight (<60 kg)
- Impaired renal function (specific creatinine clearance thresholds vary by agent)
The guidelines emphasize using manufacturer-specified dose-reduction criteria rather than arbitrary reductions, as underdosing may compromise efficacy.
When to Switch from Warfarin to a DOAC
Actively switch patients from warfarin to a DOAC if they have 1:
- Risk of intracranial hemorrhage
- Poor INR control (time in therapeutic range <70%)
This represents a proactive recommendation, not just offering DOACs to new patients.
Common Pitfalls to Avoid
Do not use bleeding risk scores to withhold anticoagulation 1. The guidelines explicitly state that bleeding risk assessment should guide management of modifiable risk factors, not decisions about whether to anticoagulate. If a patient has a CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women), they need anticoagulation regardless of bleeding risk.
Do not combine anticoagulants with antiplatelet agents unless the patient has an acute vascular event or requires interim bridging for procedures 1. This combination dramatically increases bleeding risk without proportional benefit in most scenarios.
Practical Selection Among the Four DOACs
While guidelines state all four DOACs are acceptable options, selection factors include:
- Renal function: Dabigatran and edoxaban require more significant dose adjustments with renal impairment; apixaban may be preferred in moderate renal dysfunction
- Dosing frequency: Apixaban and dabigatran require twice-daily dosing; rivaroxaban and edoxaban are once-daily
- Drug interactions: All DOACs interact with strong P-glycoprotein and CYP3A4 inhibitors/inducers, but to varying degrees
- GI tolerability: Dabigatran has higher rates of dyspepsia
The evidence does not clearly favor one DOAC over another for efficacy or safety when used appropriately 2, 4, 5, so selection often depends on patient-specific factors like renal function, adherence concerns with twice-daily dosing, and cost/insurance coverage.